Erratum: Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats (Eur Respir J (2011) 37 (1104–1118) DOI: 10.1183/09031936.00126010);Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats

European Respiratory Journal

Volumn 37, Issue 5, 2011, Pages 1104-1118

  Dumitrascu, R ^a   Kulcke, C ^a   Konigshoff M ^a   Kouri, F ^a   Yang, X ^c   Morrell, N ^c   Ghofrani, H A ^a   Weissmann, N ^a   Reiter, R ^d   Seeger, W ^a,b   Grimminger, F ^a   Eickelberg, O ^a   Schermuly, R T ^a,b   Pullamsetti, S S ^a,b  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d Ergonex Pharma GmbH   (Switzerland)

Author keywords

Collagen; Experimental therapeutics; Inflammation; Pulmonary hypertension; Smooth muscle cells; Vascular remodelling

Indexed keywords

COLLAGEN; KETANSERIN; MONOCROTALINE; PLACEBO; ROPINIROLE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN ANTAGONIST; TERGURIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL OXYGEN SATURATION; ARTERY MUSCLE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG TARGETING; FEMALE; HEART OUTPUT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; UPREGULATION;

EID: 79955663912     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.50126010     Document Type: Erratum

References (67)

1. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. S, 13S-24S.
2. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327: 70-75.
3. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113. (Pubitemid 40923321)
4. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739. (Pubitemid 23170122)
5. Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120: 1562-1569. (Pubitemid 33078473)
6. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-616. (Pubitemid 26277950)
7. Marcos E, Fadel E, Sanchez O, et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004; 94: 1263-1270. (Pubitemid 38656414)
8. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491. (Pubitemid 20100285)
9. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. (Pubitemid 34815354)
10. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157. (Pubitemid 41653106)
11. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006; 5: 689-702. (Pubitemid 44151606)
12. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
13. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005; 111: 2812-2819. (Pubitemid 40791554)
14. Guignabert C, Izikki M, Tu LI, et al. Transgenic mice over-expressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006; 98: 1323-1330. (Pubitemid 43948088)
15. Ullmer C, Schmuck K, Kalkman HO, Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 1995; 370: 215-221.
16. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
17. Kereveur A, Callebert J, Humbert M, et al. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2233-2239.
18. Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002; 8: 1129-1135.
19. Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs 1996; 51: 954-965. (Pubitemid 26164165)
20. Kren V, Eich E, Pertz HH. Pergolide, terguride and N,N′-spacer- linked oligomers of both interact with 5-HT2A receptors of rat tail artery. Physiol Res 2004; 53: 35-43. (Pubitemid 38295539)
21. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303: 791-804.
22. Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005; 513: 225-228. (Pubitemid 40616066)
23. Huxtable RJ. Activation and pulmonary toxicity of pyrrolizidine alkaloids. Pharmacol Ther 1990; 47: 371-389. (Pubitemid 20309558)
24. Rosenberg HC, Rabinovitch M. Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol 1988; 255: H1484-H1491.
25. Yu H, Konigshoff M, Jayachandran A, et al. Transgelin is a direct target of TGF-beta/Smad3-dependent epithelial cell migration in lung fibrosis. FASEB J 2008; 22: 1778-1789. (Pubitemid 351811455)
26. Rose F, Grimminger F, Appel J, et al. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J 2002; 16: 1660-1661.
27. Pullamsetti S, Krick S, Yilmaz H, et al. Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. Respir Res 2005; 6: 128.
28. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005; 115: 2811-2821. (Pubitemid 41434408)
29. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006; 113: 286-295.
30. Ermert L, Ermert M, Althoff A, et al. Vasoregulatory prostanoid generation proceeds via cyclooxygenase-2 in noninflamed rat lungs. J Pharmacol Exp Ther 1998; 286: 1309-1314. (Pubitemid 29135544)
31. Herve P, Drouet L, Dosquet C, et al. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med 1990; 89: 117-120. (Pubitemid 20196727)
32. Humbert M, Labrune P, Sitbon O, et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur Respir J 2002; 20: 59-65. (Pubitemid 34822922)
33. Delcroix M, Kurz X, Walckiers D, et al. High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium. Eur Respir J 1998; 12: 271-276. (Pubitemid 28389517)
34. Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: Suppl. 3, 195S-199S.
35. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150. (Pubitemid 32995372)
36. Eddahibi S, Morrell N, D'Ortho MP, et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002; 20: 1559-1572. (Pubitemid 35460627)
37. Rashid M, Manivet P, Nishio H, et al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci 2003; 73: 193-207. (Pubitemid 36555937)
38. Hironaka E, Hongo M, Sakai A, et al. Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003; 60: 692-699. (Pubitemid 37501127)
39. Kanai Y, Hori S, Tanaka T, et al. Role of 5-hydroxytryptamine in the progression of monocrotaline induced pulmonary hypertension in rats. Cardiovasc Res 1993; 27: 1619-1623. (Pubitemid 23297526)
40. Miyata M, Ito M, Sasajima T, et al. Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung 2000; 178: 63-73. (Pubitemid 30247111)
41. Domenighetti G, Leuenberger P, Feihl F. Haemodynamic effects of ketanserin either alone or with oxygen in COPD patients with secondary pulmonary hypertension. Monaldi Arch Chest Dis 1997; 52: 429-433. (Pubitemid 28062319)
42. Kato S, Kishiro I, Machida M, et al. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. J Int Med Res 2000; 28: 258-268. (Pubitemid 32014292)
43. Bonhaus DW, Flippin LA, Greenhouse RJ, et al. RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist. Br J Pharmacol 1999; 127: 1075-1082. (Pubitemid 29326628)
44. Shacham S, Orbach P, Marantz Y, et al. PRX-08066: A potent 5-HT2B receptor antagonist with dual disease modifying/vasodilating mechanism for the treatment of pulmonary hypertension. www.phaonlineuniv.org/sites/default/files/ presentations/abstract32,Sharon-Shacham.pdf Date last accessed: January 17, 2010. Date last updated: June 2009.
45. Porvasnik SL, Germain S, Embury J, et al. PRX-08066, a novel 5- hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats. J Pharmacol Exp Ther 2010; 334: 364-372.
46. Blanpain C, Le PE, Parma J, et al. Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension. Cardiovasc Res 2003; 60: 518-528. (Pubitemid 37501109)
47. Deraet M, Manivet P, Janoshazi A, et al. The natural mutation encoding a C terminus-truncated 5-hydroxytryptamine 2B receptor is a gain of proliferative functions. Mol Pharmacol 2005; 67: 983-991. (Pubitemid 40410400)
48. Rhodes CJ, Davidson A, Gibbs JS, et al. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009; 121: 69-88.
49. Nebigil CG, Jaffre F, Messaddeq N, et al. Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy. Circulation 2003; 107: 3223-3229. (Pubitemid 36793095)
50. Brattelid T, Tveit K, Birkeland JA, et al. Expression of mRNA encoding G protein-coupled receptors involved in congestive heart failure: a quantitative RT-PCR study and the question of normalisation. Basic Res Cardiol 2007; 102: 198-208. (Pubitemid 46566278)
51. Hauso O, Gustafsson BI, Loennechen JP, et al. Long-term serotonin effects in the rat are prevented by terguride. Regul Pept 2007; 143: 39-46. (Pubitemid 47212520)
52. Newman-Tancredi A, Rivet JM, Cussac D, et al. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol 2003; 368: 188-199. (Pubitemid 37255480)
53. 2B receptor: evidence for species differences. J Pharmacol Exp Ther 1996; 276: 720-727.
54. Nelson DL, Lucaites VL, Audia JE, et al. Species differences in the pharmacology of the 5-hydroxytryptamine2 receptor: structurally specific differentiation by ergolines and tryptamines. J Pharmacol Exp Ther 1993; 265: 1272-1279. (Pubitemid 23321030)
55. Fielden MR, Hassani M, Uppal H, et al. Mechanism of subendocardial cell proliferation in the rat and relevance for understanding drug-induced valvular heart disease in humans. Exp Toxicol Pathol 2010; 62: 607-613.
56. Forbes IT, Jones GE, Murphy OE, et al. N-(1-methyl-5-indolyl)-N′- (3-methyl-5-isothiazolyl)urea: a novel, high-affinity 5-HT2B receptor antagonist. J Med Chem 1995; 38: 855-857.
57. Polak MJ, Knight ME, Gause GE, et al. Effect of fenoldopam on preconstricted isolated salt-perfused rat lungs. J Appl Physiol 1989; 67: 1076-1080. (Pubitemid 19245031)
58. McCormack DG, Barnes PJ, Evans TW. Effects of dopexamine hydrochloride on hypoxic pulmonary vasoconstriction in isolated rat lung. Crit Care Med 1990; 18: 520-523. (Pubitemid 20164876)
59. Gorman P. Vasodilator response to dopamine in the ferret pulmonary circulation. Br J Pharmacol 1988; 94: 212-218.
60. Andersen PH, Jansen JA. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol 1990; 188: 335-347. (Pubitemid 20188391)
61. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168: 487-493. (Pubitemid 37046880)
62. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 2001; 108: 1141-1150. (Pubitemid 32995372)
63. Pitt BR, Weng W, Steve AR, et al. Serotonin increases DNA synthesis in rat proximal and distal pulmonary vascular smooth muscle cells in culture. Am J Physiol 1994; 266: L178-L186.
64. Lee SL, Wang WW, Moore BJ, et al. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res 1991; 68: 1362-1368.
65. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: Suppl. 1, S10-S19.
66. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998; 132: 16-24. (Pubitemid 28329606)
67. Dorfmuller P, Humbert M, Capron F, et al. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 9-19. (Pubitemid 36559729)